Black Swan Pharmaceuticals

Black Swan Pharmaceuticals

Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $65M

Overview

Black Swan Pharmaceuticals is a private, commercial-stage Nigerian pharmaceutical services and distribution company. Contrary to the initial data suggesting a US-based RNA & Gene Therapy focus, the company's actual operations are centered on providing affordable generic medications, medical devices, diagnostic equipment, and laboratory analysis services in West Africa. Its business model is service and distribution-oriented, targeting institutional and governmental clients to improve healthcare accessibility in developing regions. The company appears to be revenue-generating through its product sales and service offerings.

RNA & Gene Therapy

Technology Platform

Integrated pharmaceutical and medical device supply chain, distribution network, and owned diagnostic service facilities (labs, imaging centers).

Funding History

2
Total raised:$65M
Series A$50M
Seed$15M

Opportunities

Large, underserved market in Nigeria and West Africa with high demand for affordable generic drugs and reliable medical equipment.
Potential for growth through partnerships with government health initiatives and non-governmental organizations focused on public health.

Risk Factors

Faces operational risks including complex import logistics, currency volatility, and supply chain disruptions in Nigeria.
Competitive pressure in generic drug distribution and dependence on public sector spending introduce market risks.

Competitive Landscape

Operates in the competitive Nigerian pharmaceutical distribution and medical supply market, competing against other indigenous distributors and multinational companies. Differentiates through an integrated model that includes owned diagnostic service facilities alongside product distribution.